Vandetanib (ZD6474)

For research use only.

Catalog No.S1046

87 publications

Vandetanib (ZD6474) Chemical Structure

CAS No. 443913-73-3

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 147 In stock
USD 257 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vandetanib (ZD6474) has been cited by 87 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Targets
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
40 nM 110 nM 500 nM
In vitro

Vandetanib also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC50 of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC50 of 2.7 μM (A549) to 13.5 μM (Calu-6). [1] Vandetanib displays an inhibitory effect on the basal ABCG2-ATPase. Parental and ABCG2-expressing A431 cells showed similar sensitivities toward Vandetanib. Exposure to EGFR inhibitors decreases pEGFR levels in A431 cells, with Vandetanib displaying only a moderate effect. Vandetanib displays a slight but measurable effect, whereas gefitinib, pelitinib and neratinib completely inhibit ABCG2-mediated efflux of mitoxantrone from A431/ABCG2 cells, similarly to the specific ABCG2 inhibitor Ko143. [2] Vandetanib inhibits both PC3wt and PC3R cell lines with similar IC50 of 13.3 μM and 11.5 μM, respectively. [3] Vandetanib suppresses phosphorylation of VEGFR2 in HUVEC and EGFR in hepatoma cells and inhibits cell proliferation. [4] Vandetanib causes an accumulation of cells in the G0-G1 phases in GEO and OVCAR-3 cells and increases apoptosis in OVCAR-3, ZR-75-1, MCF-10A ras, and GEO cells. Vandetanib causes a dose-dependent inhibition of EGFR phosphorylation in mouse NIH-EGFR fibroblasts and human MCF-10A ras breast cancer cells, two cell lines that overexpress the human EGFR. Vandetanib treatment results in a dose-dependent inhibition of soft agar growth in seven human cell lines (breast, colon, gastric, and ovarian) with functional EGFR but lacking VEGFR2. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SN179  MkSzSpVv[3Srb36gRZN{[Xl? NIfDNmE2ODEkgJnuUeKh MoPaNVYhcA>? MmnQbY5kemWjc3XzJGNZS1J2IHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? M4G3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke2OlkyLz5{NU[3OlY6OTxxYU6=
SN186 MkLESpVv[3Srb36gRZN{[Xl? NVq5PXl{PTBy4pEJcm3DqA>? NGO5W5kyPiCq M1zvS4lv[3KnYYPld{BEYEOUNDDlfJBz\XO|aX;uJJNq\26rZnnjZY51dHl? M2Pme|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke2OlkyLz5{NU[3OlY6OTxxYU6=
SN179  M4HpSGZ2dmO2aX;uJGF{e2G7 NWjTVG13PTBy4pEJcm3DqA>? M{\oZlE3KGh? MoDS[Y5p[W6lZYOgeIhmKEO[Q1yxNkBlcXKnY4Tl[EBucWe{YYTpc44> MmjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{[2PVEoRjJ3Nke2OlkyRC:jPh?=
SN179  M{K5O2Z2dmO2aX;uJGF{e2G7 NVOycnM3PTBy4pEJcm3DqA>? M1fNb|E3KGh? NX7G[mlscW6lcnXhd4V{KGKjc3HsJI1q\3KjdHnvcuKh NHfJR5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OlY6OSd-MkW2O|Y3QTF:L3G+
Jurkat MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3NuKhcMLi M3jabGdKPTB;MT61JOKyKDBwMjFOwG0> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MUKwOUc,OjR4OEGyNFU9N2F-
K-562 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NuKhcMLi NITGPFBIUTVyPUGuPEDDuSByLkGg{txO MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MUKwOUc,OjR4OEGyNFU9N2F-
NCTC-2544 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy3NuKhcMLi Mn32S2k2OD12Lk[gxtEhOC5|IN88US=> M{LPe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkixNlA2Lz5{NE[4NVIxPTxxYU6=
A-431 M2HDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NuKhcMLi M2PmZmdKPTB;Mj60JOKyKDBwMzFOwG0> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MUKwOUc,OjR4OEGyNFU9N2F-
SK-N-SH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRWFAvPjJ3LUKwJO69VQ>? MlLkOFghcA>? NVz2[5dKTE2VTx?= MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MlfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SH-SY5Y MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELQXXIxNjZ{NT2yNEDPxE1? MXi0PEBp MlPGSG1UVw>? M1vGNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OUC3OEc,OjR|OUmwO|Q9N2F-
SK-N-SH M13IVWFxd3C2b4Ppd4khSXO|YYm= Ml7pOU8yOC9{MDFOwG0> NEDqVlk1QCCq MoS1SG1UVw>? M4nQ[Ylv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NYHpVWV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVkxPzRpPkK0N|k6ODd2PD;hQi=>
SH-SY5Y NVe2[4pvSXCxcITvd4l{cSCDc4PhfS=> Ml32OU8yOC9{MDFOwG0> NXXVW5NjPDhiaB?= MlzXSG1UVw>? MkjCbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NVLhSFR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVkxPzRpPkK0N|k6ODd2PD;hQi=>
SK-N-SH MkGzSpVv[3Srb36gRZN{[Xl? MUe1M|ExNzJyIN88US=> MkjnOFghcA>? NYTVWHV{TE2VTx?= M{ThZYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4S= M{HKPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SH-SY5Y M3nzSGZ2dmO2aX;uJGF{e2G7 MnvROU8yOC9{MDFOwG0> NFf1dWs1QCCq M1fPN2ROW09? MmrjbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dB?= M{Li[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
SK-N-SH MVHGeY5kfGmxbjDBd5NigQ>? MlPyNU82NzFyIN88US=> Mn7FOFghcA>? NHSyTJlFVVOR MUHpcohq[mm2czDSSXQheGixc4Doc5J6dGG2aX;u NF:5OZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5PVA4PCd-MkSzPVkxPzR:L3G+
SH-SY5Y NUXVOFB3TnWwY4Tpc44hSXO|YYm= Mn7BNU82NzFyIN88US=> NY\hbop7PDhiaB?= MlT6SG1UVw>? M3TIcIlvcGmkaYTzJHJGXCCyaH;zdIhwenmuYYTpc44> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OUC3OEc,OjR|OUmwO|Q9N2F-
SK-N-SH NV;MSJloTnWwY4Tpc44hSXO|YYm= M{DNSVUwOTBizszN M1W2TlQ5KGh? MWPEUXNQ MlnPbY5pcWKrdIOgbJVu[W5iTlKgZ4VtdCCvaXfyZZRqd25? NGny[pg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5PVA4PCd-MkSzPVkxPzR:L3G+
SH-SY5Y MkjhSpVv[3Srb36gRZN{[Xl? M4jEflUwOTBizszN MlrDOFghcA>? NFf1[ZNFVVOR NED2SJBqdmirYnn0d{BpfW2jbjDORkBk\WyuIH3p[5JifGmxbh?= MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SK-N-SH M3;OTmZ2dmO2aX;uJGF{e2G7 NIXzTW02NzFyIN88US=> NVXZWYpEPDhiaB?= M3S0ZmROW09? NWPtS|J5cW6qaXLpeJMhcHWvYX6gUmIh[2WubDDpcpZie2mxbh?= NGHmfoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5PVA4PCd-MkSzPVkxPzR:L3G+
SH-SY5Y NUXkRZFGTnWwY4Tpc44hSXO|YYm= M1jFTVUwOTBizszN NV7IWFlYPDhiaB?= NIDNOYlFVVOR M{L2b4lvcGmkaYTzJIh2dWGwIF7CJINmdGxiaX72ZZNqd25? NW\YTHN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVkxPzRpPkK0N|k6ODd2PD;hQi=>
SK-N-SH MVjGeY5kfGmxbjDBd5NigQ>? NVm3cWNnPSEQvF2= NEDZV4kzPC92OD:3NkBp NGTQe5VFVVOR M{nxUpN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YhS1iFUkSgZY5lKE2PUEG0JI1TVkF? MkPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SH-SY5Y MljCSpVv[3Srb36gRZN{[Xl? M{PEWFUh|ryP NWq3OIo1OjRxNEivO|IhcA>? NImyTpJFVVOR Mknud5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBEYEOUNDDhcoQhVU2SMUSgcXJPSQ>? NWewXZJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVkxPzRpPkK0N|k6ODd2PD;hQi=>
SK-N-SH MVXGeY5kfGmxbjDBd5NigQ>? M3P6RVUh|ryP M3;MbFQ5Nzd{IHi= MmCxSG1UVw>? M{XxT5N2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjD0bIUhS1iFUkSgZY5lKE2PUEG0JJBzd3SnaX6= MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OUmwO|QoRjJ2M{m5NFc1RC:jPh?=
SH-SY5Y MmLnSpVv[3Srb36gRZN{[Xl? NF2w[ow2KM7:TR?= MVq0PE84OiCq Ml3zSG1UVw>? MnOyd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIITo[UBEYEOUNDDhcoQhVU2SMUSgdJJwfGWrbh?= M2LqOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m5NFc1Lz5{NEO5PVA4PDxxYU6=
HMEpC M{XjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;NWnB1OSCwTT2xNFAh|ryP MX20POKhcMLi NGrJNIxFVVOR MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NX3vNY5SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN|g5PDNpPkK0NVM5QDR|PD;hQi=>
MCF-7 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxJI5ONTFyMDFOwG0> MnrUOFjDqGkEoB?= MorsSG1UVw>? MnzxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|OEi0N{c,OjRzM{i4OFM9N2F-
ZR-75-1 NGjSfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nvcVEhdk1vMUCwJO69VQ>? NIfk[Io1QMLiaNMg MojTSG1UVw>? M4W0dIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|OEi0N{c,OjRzM{i4OFM9N2F-
MDA-MB-231 M{fJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTSNUBvVS1zMECg{txO NUWyVoxmPDkEoHlCpC=> NX3tNZYxTE2VTx?= MmDCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M37mfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO4PFQ{Lz5{NEGzPFg1OzxxYU6=
MDA-MB-468 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XkUlEhdk1vMUCwJO69VQ>? MnXTOFjDqGkEoB?= M{TFdWROW09? MlO2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{i4OFMoRjJ2MUO4PFQ{RC:jPh?=
T-47-D NWP4S5dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxJI5ONTFyMDFOwG0> MlL1OFjDqGkEoB?= MlPtSG1UVw>? NEKx[nBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NYC0dlN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN|g5PDNpPkK0NVM5QDR|PD;hQi=>
U251  MUjGeY5kfGmxbjDBd5NigQ>? MXiyM|QwQOLCid885qS{yqB? M37tNlYwOTJxMkSgbC=> NG\nO4RFVVOR MXXpcoNz\WG|ZYOgeIhmKEyFMz3JTUBt\X[nbDDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1vjPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{m5PFUzLz5{M{e5PVg2OjxxYU6=
U87MG NXHKPVBYTnWwY4Tpc44hSXO|YYm= M2HIRlIwPC964pEJ{tzjjLQEoB?= NFnXSWQ3NzF{L{K0JIg> NVH4PGo4TE2VTx?= NWnmeWpEcW6lcnXhd4V{KHSqZTDMR|MuUUlibHX2[YwhcW5iYTD0bY1mNWSncHXu[IVvfCCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz M{TGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{m5PFUzLz5{M{e5PVg2OjxxYU6=
U251  MXrGeY5kfGmxbjDBd5NigQ>? MYW05qCK|r{khMRCpC=> M{ntcFIwPi9zMjDo MmTpSG1UVw>? NYTBVXJEe3WycILld5NmeyCkYYPhcEBt\X[nbIOgc4YheGixc4Doc5J6dGG2aX;uJI9nKFN4IDjTNlM2NzJ|NjmsJFRGNUKSMTCoWFM4NzR4KTygZY5lKEGtdDCoV|Q4OyliaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7OUi1Nkc,OjN5OUm4OVI9N2F-
U87MG NEXWWplHfW6ldHnvckBCe3OjeR?= M164blTjiIoQvPMEt:Kh M4jIRVIwPi9zMjDo NHzyPZVFVVOR NIfQfZh{fXCycnXzd4V{KGKjc3HsJIxmfmWuczDv[kBxcG:|cHjvdplt[XSrb36gc4YhWzZiKGOyN|UwOjN4KTygOGUuSlBzIDjUN|cwPDZrLDDhcoQhSWu2IDjTOFc{MSCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi M2LOeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{m5PFUzLz5{M{e5PVg2OjxxYU6=
H1650  M{jDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqxTWM2OD1|LkZCtVEvOiEQvF2= NWjqOotLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyO|Q4PThpPkKzNlc1PzV6PD;hQi=>
HUVECs  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzh[FM4OiCq MonJTWM2OMLiPTC3MlEh|ryvb3yvUC=> MkHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUGwNlcoRjJ{NkGxNFI4RC:jPh?=
KYN-2  NYfUOoloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfrbXY4PzJiaB?= NITpZnZKSzVywrC9JFgvOSEQvH3vcE9N Mne4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUGwNlcoRjJ{NkGxNFI4RC:jPh?=
HuH-7  M1rWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH3THI4OiCq M1LPb2lEPTEEoE2gPU41KM7:bX;sM2w> MmC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MUGwNlcoRjJ{NkGxNFI4RC:jPh?=
HUVECs  NW\YNmVwTnWwY4Tpc44hSXO|YYm= M4jyS|EwPS9zMDFOwG0> M3HQS|EhcA>? NF:wbVd{cWewaX\pZ4FvfGy7IHnubIljcXS|IG\FS2ZTNTJicHjvd5Bpd3K7bHH0bY9v NILodlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[xNVAzPyd-MkK2NVExOjd:L3G+
HAK1-B MX\GeY5kfGmxbjDBd5NigQ>? MoXWNU82NzFyIN88US=> M1zSbVEhcA>? M{TKZpN2eHC{ZYPz[ZMhTUeIUjDwbI9{eGixconsZZRqd25? M3H0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkGxNFI4Lz5{Mk[xNVAzPzxxYU6=
UM-22A NEfJd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLBNnVjOC14IN88US=> MojaO|IhcA>? NEnYbIJFVVOR Mm\1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2riTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
UM-22B NX3LSHFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nsUlAuPiEQvF2= NV60[FNKPzJiaB?= MVLEUXNQ MlribY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2nwR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-37A MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr5WXUxNTZizszN NV7lR4FYPzJiaB?= NUK2dZF{TE2VTx?= NFHXTlBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
PCI-37B MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqxUXMxNTZizszN NGHhXGM4OiCq MYLEUXNQ NHzuNoJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{f6dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-15B MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq4NE03KM7:TR?= NYTWfpRGPzJiaB?= MUXEUXNQ MnTsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
SCC-25 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TrSFAuPiEQvF2= M{f4[VczKGh? NIi1NoFFVVOR NUTEWpYxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
UM-22A MXjGeY5kfGmxbjDBd5NigQ>? NYjNOYx[OC1zMDFOwG0> NHPXR5YzPCCq MXHEUXNQ MkDGbY5pcWKrdIOgeIhmKGGldHn2ZZRqd25ib3[geIhmKEWJRmKgeJlzd3OrbnWgb4lv[XOnIHHu[EBidHOxIHTlZ5Jm[XOnczD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCob4Ltd{Bw\iC2aHWg[I94dnO2cnXhcUB{cWewYXzpcoch\WynbXXueJMtKFOWQWSzJIFv\CCPQWDL NVT2UY5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNFc4OzVpPkKyN|A4PzN3PD;hQi=>
UM-22B MkXmSpVv[3Srb36gRZN{[Xl? NVrHSmhXOC1zMDFOwG0> NUO1T29GOjRiaB?= M{\VcmROW09? NEDMdI9qdmirYnn0d{B1cGViYXP0bZZifGmxbjDv[kB1cGViRVfGVkB1gXKxc3nu[UBscW6jc3WgZY5lKGGuc3:g[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIH\vdo1{KG:oIITo[UBld3ewc4Ty[YFuKHOrZ37hcIlv\yCnbHXt[Y51eyxiU2TBWFMh[W6mIF3BVGs> Mk\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MEe3N|UoRjJ{M{C3O|M2RC:jPh?=
PCI-15B NYi5XoZNTnWwY4Tpc44hSXO|YYm= MUOwMVExKM7:TR?= NV3mcWxDOjRiaB?= NGHvUIdFVVOR MVfpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjD0bIUhTUeIUjD0fZJwe2mwZTDrbY5ie2ViYX7kJIFte29iZHXjdoVie2W|IITo[UBmgHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIVlKG[xcn3zJI9nKHSqZTDkc5dve3S{ZXHtJJNq\26jbHnu[{BmdGWvZX70d{whW1SDVEOgZY5lKE2DUFu= NH7zTWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwO|c{PSd-MkKzNFc4OzV:L3G+
PCI-37A NYDj[JJ1TnWwY4Tpc44hSXO|YYm= NEj0bpQyKM7:TR?= Mn\ENlQhcA>? NXTPOVdkTE2VTx?= MmTu[I94dnKnZ4XsZZRmeyCYRVfGJJBzd2S3Y4Tpc44> M4jU[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
UM-22A Mm\PSpVv[3Srb36gRZN{[Xl? NWjVOGliOSEQvF2= NV;rSVcyOjRiaB?= MYHEUXNQ MYjkc5dvemWpdXzheIV{KF[HR1[gdJJw\HWldHnvci=> NFPXVmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwO|c{PSd-MkKzNFc4OzV:L3G+
PCI-15B M4PHVmZ2dmO2aX;uJGF{e2G7 M3r6XVEh|ryP MYKyOEBp NVnSSpl3TE2VTx?= NYezOVd{\G:5boLl[5Vt[XSnczDWSWdHKHC{b3T1Z5Rqd25? M2PNZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
PCI-15B MYLJcpZie2mxbjDBd5NigQ>? MYmyOEBp NWnnPIxvTE2VTx?= MWjFR|UxRTV3ODDuUS=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
PCI-37A M3m0fWlvfmG|aX;uJGF{e2G7 NIHSeWszPCCq NFLWVZpFVVOR NEP1d5NGSzVyPUG2PVUhdk1? M3zYZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{C3O|M2Lz5{MkOwO|c{PTxxYU6=
UM-22A MnnWTY53[XOrb36gRZN{[Xl? M1rEZVI1KGh? M2roO2ROW09? Mm[4SWM2OD1yLkOgcm0> NU\tRVFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNFc4OzVpPkKyN|A4PzN3PD;hQi=>
SCC-25 M4TqWGlvfmG|aX;uJGF{e2G7 M4LLdFI1KGh? MXfEUXNQ M{jhV2VEPTB;MUCgcm0> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyN{ezOUc,OjJ|MEe3N|U9N2F-
UM-22B MVrJcpZie2mxbjDBd5NigQ>? MWKyOEBp NXmxPY1PTE2VTx?= NHm2RotGSzVyPUK0NlQhdk1? MlfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MEe3N|UoRjJ{M{C3O|M2RC:jPh?=
PCI-37B NHvuNlZKdn[jc3nvckBCe3OjeR?= MVOyOEBp MWXEUXNQ MXHFR|UxRTF5Mk[gcm0> NHnifIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwO|c{PSd-MkKzNFc4OzV:L3G+
201T MV7GeY5kfGmxbjDBd5NigQ>? MXOyMlUh|ryP MnHTOFghcA>? MlrhSG1UVw>? MWPpcohq[mm2czDwbI9{eGixLV3BVGsh\m:ubH;3bY5oKEWJRh?= M1vrcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW4OFc3Lz5{MkK1PFQ4PjxxYU6=
273T  MWjGeY5kfGmxbjDBd5NigQ>? Mo\GNk42KM7:TR?= NVrNNm1xPDhiaB?= NX7BZpJJTE2VTx?= M4O4dolvcGmkaYTzJJBpd3OyaH:tUWFRUyCob3zsc5dqdmdiRVfG NXG0NodIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVg1PzZpPkKyNlU5PDd4PD;hQi=>
A549 NGKzVJVHfW6ldHnvckBCe3OjeR?= MWCyMlUh|ryP NVzRSYI5PDhiaB?= MnG1SG1UVw>? M{jMbIlvcGmkaYTzJJBpd3OyaH:tUWFRUyCob3zsc5dqdmdiRVfG NUPL[4FrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVg1PzZpPkKyNlU5PDd4PD;hQi=>
201T  NX:5cnVvTnWwY4Tpc44hSXO|YYm= MVWxM|UwOTBizszN MXe0PEBp MXLEUXNQ NGfXZ5hjdG:la4OgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgbY5lfWOnZDDifUBXTUeIQx?= NIHyWVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK1PFQ4Pid-MkKyOVg1PzZ:L3G+
H2052 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHUdlNKSzVyPUGuNFfDuTBwMESg{txO NFy4fo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm3NFg4PCd-MkG5O|A5PzR:L3G+
H2452 NGjmTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\lTWM2OD1|LkWyxtEyNjF|IN88US=> NGrpOo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm3NFg4PCd-MkG5O|A5PzR:L3G+
H28 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULBSWc6UUN3ME2wMlMzyrFyLkC3JO69VQ>? MoHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7N{C4O|QoRjJzOUewPFc1RC:jPh?=
MSTO-211H MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Pxe2lEPTB;MT60NuKyOC5yMzFOwG0> M1TxNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUewPFc1Lz5{MUm3NFg4PDxxYU6=
Hth83 M1vLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLJdFk4OiCq M2\MVWROW09? NEf3Oo1KSzVyPUOuN|AhyrFiMD62OkDPxE1? MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MkC0O|coRjJzMkKwOFc4RC:jPh?=
C643 M13ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfzUnQ4OiCq MnTtSG1UVw>? NYTHe4QyUUN3ME2zMlY2KMLzIEGuNlIh|ryP NYn1WJYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNlA1PzdpPkKxNlIxPDd5PD;hQi=>
8505C M1TCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHlfoU4OiCq M2LifWROW09? M2LJdGlEPTB;Nz61OkDDuSBzLkGzJO69VQ>? M2D0dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkKwOFc4Lz5{MUKyNFQ4PzxxYU6=
Hth74 NVXzeGd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHrZZJrPzJiaB?= MnXvSG1UVw>? MnyyTWM2OD16LkW2JOKyKDFwMEGg{txO MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{MES3O{c,OjF{MkC0O|c9N2F-
SW1736 M2LTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzCTWo4OiCq MX7EUXNQ NX;KWoI1UUN3ME25MlA2KMLzIECuOVUh|ryP MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{MES3O{c,OjF{MkC0O|c9N2F-
Hth7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qwfVczKGh? NYjRWZRrTE2VTx?= M2XPZWlEPTB;OT62OkDDuSByLkO4JO69VQ>? M3HHVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkKwOFc4Lz5{MUKyNFQ4PzxxYU6=
Hth104 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi3NkBp M3TF[2ROW09? MWHJR|UxRcLzMU[uPVghyrFiTlGg{txO NYT5SGZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNlA1PzdpPkKxNlIxPDd5PD;hQi=>
HTB3 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiwMVIxKM7:TR?= M4rGdlI1yqCq NIDlZ3BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3jxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKwNlU3Lz5zOUKyNFI2PjxxYU6=
HT1376 M13hS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMVIxKM7:TR?= MYOyOOKhcA>? M4L0ZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIn5NnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNFI2Pid-MUmyNlAzPTZ:L3G+
RT4 NGDUOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzSNE0zOCEQvF2= M1jLOVI1yqCq NXLBVlRMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M17zUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKwNlU3Lz5zOUKyNFI2PjxxYU6=
J82 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fa[VAuOjBizszN NITqTHIzPMLiaB?= Mny2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2rtdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKwNlU3Lz5zOUKyNFI2PjxxYU6=
CRL1749 NHrmdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLiV|h2OC1{MDFOwG0> NV7xOYhiOjUEoHi= NWWzRW41cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MnjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkCyOVYoRjF7MkKwNlU3RC:jPh?=
T24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rmVFAuOjBizszN M{XnclI1yqCq MmHjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4fOWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKwNlU3Lz5zOUKyNFI2PjxxYU6=
SUP NWL3UZg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TLcVAuOjBizszN MoLMNlTDqGh? NFX5bW9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NETQ[FU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNFI2Pid-MUmyNlAzPTZ:L3G+
HTB9 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWewMVIxKM7:TR?= NYTGZYFQOjUEoHi= NXLxNWpHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkCyOVYoRjF7MkKwNlU3RC:jPh?=
ACC3 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnJNE0yOCEQvF2= M1jqR|czKGh? NHjJNVNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVHxbIVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVgxOjVpPkG4Olk5ODJ3PD;hQi=>
ACC2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXhNZgxNTFyIN88US=> MoTtO|IhcA>? M1:2UYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1jYNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nkm4NFI2Lz5zOE[5PFAzPTxxYU6=
ACCM MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Ph[|AuOTBizszN NEPKXZQ4OiCq NHruXpJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGXLXVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5PFAzPSd-MUi2PVgxOjV:L3G+
ACC3 MkDlRZBweHSxc3nzbUBCe3OjeR?= MnzoNE0yOCEQvF2= Mnj6O|IhcA>? MWDpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M1SwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nkm4NFI2Lz5zOE[5PFAzPTxxYU6=
ACC2 M172dWFxd3C2b4Ppd4khSXO|YYm= MnX3NE0yOCEQvF2= MnO1O|IhcA>? NVjDeGdbcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NIDKSpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5PFAzPSd-MUi2PVgxOjV:L3G+
ACCM NFj5fZRCeG:ydH;zbZNqKEG|c3H5 M4X1XlAuOTBizszN M2DuUVczKGh? M{\sVolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= M4GzS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nkm4NFI2Lz5zOE[5PFAzPTxxYU6=
EHMES-1 M3vXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq3NkBp NF3CZVFFVVOR NX\oXldGUUN3ME2xNE43KM7:TR?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN4NEK0PEc,OTh|NkSyOFg9N2F-
EHMES-10 NHe1WmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRO|IhcA>? Mon2SG1UVw>? MnHWTWM2OD1yLkOg{txO M{XtN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[0NlQ5Lz5zOEO2OFI1QDxxYU6=
211H MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi3NkBp NYfPWFdCTE2VTx?= MofETWM2OD1{LkKg{txO NGPheHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO2OFI1QCd-MUizOlQzPDh:L3G+
H28 M1;qVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\NO|IhcA>? MmnZSG1UVw>? MXvJR|UxRTFwODFOwG0> NWPTS4JNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOlQzPDhpPkG4N|Y1OjR6PD;hQi=>
H2052 NVjqfnRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnIOGQ4PzJiaB?= NEDvd4VFVVOR MUDJR|UxRThwMDFOwG0> MnfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|NkSyOFgoRjF6M{[0NlQ5RC:jPh?=
H2452 NV3yRldWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ZZVczKGh? NV;IPFF6TE2VTx?= NYHKTpRlUUN3ME21MlUh|ryP NV7oSJE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOlQzPDhpPkG4N|Y1OjR6PD;hQi=>
CNE-1 M3W2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF35VJoxNjFvMkWuOkDPxE1? MljwOFghcA>? NIjFNW5KSzVyPUOuOkDPxE1? NGrwOoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[zNVY1Pid-MUe2N|E3PDZ:L3G+
CNE-2 M1rGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpNoUxNjFvMkWuOkDPxE1? M3HOeFQ5KGh? NGXLSFJKSzVyPU[uNkDPxE1? NIXxOpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[zNVY1Pid-MUe2N|E3PDZ:L3G+
C666-1 NYjTXXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C4SlAvOS1{NT62JO69VQ>? MVq0PEBp NGPVbo1KSzVyPUKzMlQh|ryP Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4M{G2OFYoRjF5NkOxOlQ3RC:jPh?=
CNE-1 NYXqNZJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2wMlEuOjVwNjFOwG0> MVe3NkBp NEnaPIhKSzVyPUKuN{DPxE1? M374VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkOxOlQ3Lz5zN{[zNVY1PjxxYU6=
CNE-2 NGPtfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nLSFAvOS1{NT62JO69VQ>? MWi3NkBp MVzJR|UxRTNwNjFOwG0> MorkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4M{G2OFYoRjF5NkOxOlQ3RC:jPh?=
C666-1 NVrNU5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r5dFAvOS1{NT62JO69VQ>? M2K3NFczKGh? NYP4R3hIUUN3ME20Mlg3KM7:TR?= NH;FU|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[zNVY1Pid-MUe2N|E3PDZ:L3G+
CNE-1 NFvucWNHfW6ldHnvckBCe3OjeR?= MmnFOkDPxE1? MXiyOEBp MVLk[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= NUjkdmoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N|E3PDZpPkG3OlMyPjR4PD;hQi=>
CNE-2 NF\ZfWpHfW6ldHnvckBCe3OjeR?= NGPMTW83KM7:TR?= NFPQfIczPCCq M4j6XIRmdGG7czDHNE9IOSClZXzsJIN6[2ynIIDyc4dz\XO|aX;u MmTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4M{G2OFYoRjF5NkOxOlQ3RC:jPh?=
C666-1 NYnH[FY3TnWwY4Tpc44hSXO|YYm= NX61O2JFPiEQvF2= M3r5WVI1KGh? MkfN[IVt[Xm|IFewM2cyKGOnbHygZ5lkdGVicILv[5Jme3Orb36= NWPRS5hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N|E3PDZpPkG3OlMyPjR4PD;hQi=>
KDR15 MljlSpVv[3Srb36gZZN{[Xl? NYPjbmdjUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KF[HR1[gd5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTOiCneIDy[ZN{\WRiaX6gT2RTOTViY3XscJMtKEmFNUCgQUAxNjBzNTFOwG0v NGmySGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwNlc6Pyd-MU[zNFI4QTd:L3G+
Sf9 MVvGeY5kfGmxbjDhd5NigQ>? M1rFR2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiaHnzeIllcW6nLYTh[4dm\CCURWSgLFcxOC1zMEKwLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JGVNUVODLDDJR|UxKD1iMD6wPVch|ryPLh?= NEjEN3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwPVYyQCd-MkC0NFk3OTh:L3G+
TPC1 M{TuRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MnnlO|IhcHK| NUXVe2NYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUVGMyKGOnbHzzJIV5eHKnc4PpcochWkWWL2DDWFEh[W[2ZYKgO|IhcHK|IHL5JHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNVE3KM7:TT6= NE\Ze4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwPVYyQCd-MkC0NFk3OTh:L3G+
HEK293 M2H0[WZ2dmO2aX;uJIF{e2G7 M13zeGlvcGmkaYTpc44hd2ZiRlfGVlEwXkWJRmKyJINpcW2ncnnjJINwdnO2coXjeEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIJ6KEWOSWPBMEBGTDVyIE2gNE4yPSEQvF2u NWD5bFg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNFEyPTVpPkG5NVAyOTV3PD;hQi=>
Sf21 NX3NOFNtTnWwY4Tpc44h[XO|YYm= NGfhZnAyPSCvaX7z NWnke|lDUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJcXNvdHHn[4VlKGi3bXHuJGtFWiCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmNlEh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxOUBucW6|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCyNEBucW6|IHL5JGhVWkZiYYPzZZktKEmFNUCgQUAxNjF5NTFOwG0v M324XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe0O|QyLz5{Nki3OFc1OTxxYU6=
umbilical vein endothelial cells NV7t[4pxTnWwY4Tpc44h[XO|YYm= NHfDRotKdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIIXtZoltcWOjbDD2[YlvKGWwZH;0bIVtcWGuIHPlcIx{NCCLQ{WwJF0hOC52IN88UU4> NFzqPHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUe0N|IxOid-MUW3OFMzODJ:L3G+
BA/F3 Ml\JSpVv[3Srb36gZZN{[Xl? NF3jcGc1QCCqcoO= NVnPRXZlUW6qaXLpeIlwdiCxZjDLTWY2Si:URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlQh|ryPLh?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
BA/F3 NYWyTlFLTnWwY4Tpc44h[XO|YYm= NW[1Wo1lPDhiaILz MUTJcohq[mm2aX;uJI9nKEuGUjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KEOnbHygeIl1emViZ3zvMYJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuOlMh|ryPLh?= NVnKc4FZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O|Q4PDFpPkK2PFc1PzRzPD;hQi=>
umbilical vein endothelial cells MV\GeY5kfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGKjc3njJGZITi2rbnT1Z4VlKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6geY1jcWyrY3HsJJZmcW5iZX7kc5Rp\WyrYXygZ4VtdHNuIFnDOVAhRSBzLkKg{txONg>? M2HlTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{SzNlAzLz5zNUe0N|IxOjxxYU6=
HL60 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MV23NkBpenN? M{TzOWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMT60PVIh|ryPLh?= NIfvbGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OVUzPyd-Mk[5PVU2Ojd:L3G+
293 NWOybW1QTnWwY4Tpc44h[XO|YYm= NXjpT5JLUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KF[HR1\SNkB1emGwc3nlcpRtgSC2cnHud4Zm[3SnZDDpckAzQTNiYXTlco93cXK3czD0doFve2[nY4Tl[EBscWSwZYmgZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSBzLk[2JO69VS5? MlrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ{N{WwO|IoRjF4Mke1NFczRC:jPh?=
293 MlqwSpVv[3Srb36gZZN{[Xl? NYL3d2xQUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gNlk{KGGmZX7veolzfXNidILhcpNn\WO2ZXSgb4lldmW7IHPlcIx{KGK7IHPlcIwu[mG|ZXSgSWxKW0FiYYPzZZktKEmFNUCgQUAyNjZ4IN88UU4> M3XLd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4M{KxOVMyLz5zNkOyNVU{OTxxYU6=
HEK293 NXHsVmJDTnWwY4Tpc44h[XO|YYm= NIn1dHdKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44hcW5iSFXLNlk{KGOnbHzzJIJ6KGOnbHytZoF{\WRiRVzJV2EtKEmFNUCgQUAyNjZ4IN88UU4> NG\Gcms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS2NFk{Pid-MU[0OlA6OzZ:L3G+
HT-29 MoT2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHzHToQ4OiCqcoO= NI\zcmNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlkzPSEQvF2u M2e0NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUm1OVI4Lz5{Nkm5OVUzPzxxYU6=
DU145 MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHSwVGw4OiCqcoO= MoLKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGVUG0OUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMT65O|Qh|ryPLh?= NEjmbnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OVUzPyd-Mk[5PVU2Ojd:L3G+
MGHU3 NGLYVnZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX63NkBpenN? MojhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPR1jVN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEKuOUDPxE1w MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODNyOU[3NUc,OzB|MEm2O|E9N2F-
A549 M4KwcWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4DoSVczKGi{cx?= MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFnDOVAhRSB{LkWg{txONg>? Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|MEm2O|EoRjNyM{C5OlcyRC:jPh?=
RT112 NWHwUYdkSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M4K5SFczKGi{cx?= MnzHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUVEGxNkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEKuOUDPxE1w NEXWWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEOwPVY4OSd-M{CzNFk3PzF:L3G+
A549 MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MlXEO|IhcHK| NHv5SnZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuOlMh|ryPLh?= NUHB[4VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVU2OjdpPkK2PVk2PTJ5PD;hQi=>
CHO M2\iXmZ2dmO2aX;uJIF{e2G7 NUHVOI5ZUW6qaXLpeIlwdiCxZjDWSWdHWiCrbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25ib3[gbJVu[W5iVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiB{IDjWSWdHWjJrIITyZY5{\mWldHXkJIlvKEOKTzDj[YxteyxiSVO1NEA:KDJwNkezJO69VS5? MnrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2N{ezOVIoRjF{NEe3N|UzRC:jPh?=
MCF7 MlrXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NGDqUm84OiCqcoO= M{joTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMz61N|Yh|ryPLh?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl7NUWyO{c,OjZ7OUW1Nlc9N2F-
PANC1 NY\rTZFqSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2K2W|czKGi{cx?= MnvaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQV7DNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iND6xNFch|ryPLh?= M3PoVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUm1OVI4Lz5{Nkm5OVUzPzxxYU6=
HT-29 NIK0fZVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3;wOlExKHWP MXe3NkBpenN? NXXrdJJySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BifCBzMDD1UUBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gOE4zKM7:TT6= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN3M{W0Okc,OjF|NUO1OFY9N2F-
EAhy926 M{W0W2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2PzdFExKHWP NHrR[Vc4OiCqcoO= MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWDaIm5NlYh[2WubIOgZZQhOTBidV2gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEWuNUDPxE1w NWjRZVRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOVM2PDZpPkKxN|U{PTR4PD;hQi=>
MCF7 Mn\qRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3rLV|Q5KGi{cx?= M4TlZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMUGuPFMh|ryPLh?= M3;X[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5Nki4NVgxLz5{N{[4PFE5ODxxYU6=
MCF7 MX3DfZRwfG:6aXPpeJkh[XO|YYm= NXPPS4lLPDhiaILz NGe0TGhEgXSxdH;4bYNqfHliaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG2MlUzKM7:TT6= NU\ZcmVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OFIyOTNpPkK4PVQzOTF|PD;hQi=>
MCF7 MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M1T4SVQ5KGi{cx?= M3v2[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMUiuOUDPxE1w NXjucGdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OFE{PThpPkK2O|QyOzV6PD;hQi=>
MCF7 MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUe0PEBpenN? M2TiOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMUiuOUDPxE1w MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NUWxPUc,OjZ2N{W1NVk9N2F-
HT-29 MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn\QOFghcHK| MlfFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMUiuPVUh|ryPLh?= NHmzUJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[4PFE5OCd-Mke2PFgyQDB:L3G+
H460 MmmyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXq0PEBpenN? NIHHcmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEO3MlEh|ryPLh?= NIXlT2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[4PFE5OCd-Mke2PFgyQDB:L3G+
A673 MWXxTHRUKGG|c3H5 M3j4cpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NWCzZnE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY NWPPTpRieUiWUzDhd5NigQ>? NUXWZYRleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= NHPrTIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NFjMfoVyUFSVIHHzd4F6 M2fRXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= NUn4XFlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD NITCbIVyUFSVIHHzd4F6 M17GWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NX\HTmN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH MUTxTHRUKGG|c3H5 NUGwfWVzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NFXqV3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NGHKN4pyUFSVIHHzd4F6 NGS5UXhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 MY\xTHRUKGG|c3H5 MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| M2X1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MorGdWhVWyCjc4PhfS=> MmrOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M{f5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NHOzfmdyUFSVIHHzd4F6 M4rLTJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? NHPEWmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NHPmXnJyUFSVIHHzd4F6 MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MlOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NIXB[pRyUFSVIHHzd4F6 MlLWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> NX3LNFJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC Mn36dWhVWyCjc4PhfS=> M1e4VZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NGeydWtyUFSVIHHzd4F6 Mo\GdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| M17wW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M4TGdpFJXFNiYYPzZZk> NFfpUYdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR ; 

PubMed: 20629091     


Dose-dependent inhibition of EGFR phosphorylation by vandetanib in the human HNSCC cell lines FaDu, and SCC61. Cells were serum-starved, treated for 90 min with vandetanib at the indicated concentrations, and then stimulated for 15 min with 50 ng/ml EGF. Whole-cell lysates were obtained and subjected to Western immunoblotting to resolve proteins. Antibodies to total (unphosphorylated) receptors and β-actin were used as protein loading controls.

p-ERK / ERK / p-AKT / AKT ; 

PubMed: 19622715     


Logarithmically growing U87 and T98G cells were incubated with varying concentrations of vandetanib for 24 h. The cells were lysed, and equal amounts of proteins were separated by SDS-PAGE and probed with specific antibodies against phospho-ERK, and phospho-Akt. Western blot analysis was performed as described under Materials and Methods. The blots were subsequently stripped and reprobed against total ERK, Akt, or β-actin. 

20629091 19622715
Growth inhibition assay
Cell viability; 

PubMed: 24261856     


(A) MTT assays of HUVEC with α-santalol, vandetanib or sunitinib, respectively. (B) MTT assays of PC-3 cells with α-santalol, vandetanib or sunitinib, respectively.

24261856
In vivo Vandetanib (2.5 mg/kg, i.v.), reverses a VEGF-induced hypotension by 63% but does not significantly affect a bFGF-induced hypotension. Vandetanib (100 mg/kg) inhibits the tumor-induced blood vessel formation by 79%. Vandetanib (12.5-100 mg/kg, orally) shows great tumor growth inhibition in human tumor xenografts including Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung, with little effects on body weight. [1] In PC3wt xenografts, administration of Vandetanib alone exerts paradoxical tumor growth stimulating effects. In PC3R xenografts, the low dose of Vandetanib (25 mg/kg) has no significant effect relative to control, whereas the high dose (50 mg/kg) significantly inhibits tumor growth compared with control. In contrast, the high-dose combination reveals a significant negative interaction between Vandetanib 50 mg/kg and docetaxel 30 mg/kg in PC3R cells. [3] In tumor-bearing mice, Vandetanib suppresses phosphorylation of VEGFR2 and EGFR in tumor tissues, significantly decreases tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and up-regulates VEGF, TGF-alpha and EGF in tumor tissues. Treatment with Vandetanib is not associated with serious adverse events, including ALT abnormality, bone marrow suppression or body weight loss. [4] Vandetanib treatment of nude mice bearing palpable GEO colon cancer xenografts (which are sensitive to inhibition of EGFR signaling) induces dose-dependent tumor growth inhibition. [5]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase inhibition:

Vandetanib is incubated with enzyme, 10 mM MnCl2, and 2 μM ATP in 96-well plates coated with a poly(Glu, Ala, Tyr) 6:3:1 random copolymer substrate. Phosphorylated tyrosine is then detected by sequential incubation with a mouse IgG anti-phosphotyrosine 4G10 antibody, a horseradish peroxidase-linked sheep antimouse immunoglobulin antibody, and 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid). This methodology is adapted to examine selectivity versus tyrosine kinases associated with EGFR, PDGFRβ, Tie-2, FGFR1, c-kit, erbB2, IGF-1R, and FAK. All enzyme assays (tyrosine or serine-threonine) used appropriate ATP concentrations at or just below the respective Km (0.2–14 μM). Selectivity versus serine-threonine kinases (CDK2, AKT, and PDK1) is examined using a relevant scintillation proximity-assay (SPA) in 96-well plates. CDK2 assays contained 10 mM MnCl2, 4.5 μM ATP, 0.15 μCi of [γ-33 P]ATP/reaction, 50 mM HEPES (pH 7.5), 1 mM DTT, 0.1 mM sodium orthovanadate, 0.1 mM sodium fluoride, 10 mM sodium glycerophosphate, 1 mg/mL BSA fraction V, and a retinoblastoma substrate (part of the retinoblastoma gene, 792–928, expressed in a glutathione S-transferase expression system; 0.22 μM final concentration). Reactions are allowed to proceed at room temperature for 60 minutes before quenching for 2 hours with 150 μL of a solution containing EDTA (62 mM final concentration), 3 μg of a rabbit immunoglobulin anti-glutathione S-transferase antibody and protein A SPA-polyvinyltoluene beads (0.8 mg/reaction). Plates are then sealed, centrifuged (1200× g for 5 minutes), and counted on a Microplate scintillation counter for 30 seconds.
Cell Research:

[1]

- Collapse
  • Cell lines: Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) and Lewis Lung cells
  • Concentrations: 0.1–100 μM
  • Incubation Time: 72 hours
  • Method:

    Tumor cells are plated in their respective media at predetermined densities that are known to enable logarithmic cell growth during the period of assay (PC-3, 500 cells/well; all others, 1000 cells/well). Plates are incubated for 24 hours (37 °C with CO2) before the addition of Vandetanib (0.1–100 μM) or vehicle (0.1% DMSO in medium). Plates are reincubated for an additional 72 hours before assessing cell proliferation by [3 H]thymidine incorporation by a beta counter.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Female athymic (nu/nu genotype) Swiss mice with PC-3, Calu-6, SKOV-3, and MDA-MB-231 tumors
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 50 mg/kg/day, or 100 mg/kg/day
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.41 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.35
Formula

C22H24BrFN4O2

CAS No. 443913-73-3
Storage powder
in solvent
Synonyms N/A
Smiles CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02530411 Unknown status Drug: Fulvestrant|Drug: Vandetanib Neoplasms Velindre NHS Trust|Cancer Research UK|AstraZeneca April 2015 Phase 2
NCT01876784 Active not recruiting Drug: Vandetanib (SAR390530)|Drug: Placebo Differentiated Thyroid Cancer Genzyme a Sanofi Company|Sanofi September 17 2013 Phase 3
NCT01661179 Completed Drug: Vandetanib 300mg Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Genzyme a Sanofi Company|Sanofi November 2012 Phase 1|Phase 2
NCT01586624 Completed Drug: Vandetanib Selumetinib Cancer|Non Small Cell Lung Cancer Cancer Research UK|AstraZeneca January 10 2012 Phase 1
NCT01004419 Withdrawn Drug: ZD6474 (vandetanib)|Drug: Faslodex (Fulvestrant) Carcinoma Non Small Cell Lung University of Wisconsin Madison|AstraZeneca|University of Pittsburgh November 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Vandetanib (ZD6474) | Vandetanib (ZD6474) supplier | purchase Vandetanib (ZD6474) | Vandetanib (ZD6474) cost | Vandetanib (ZD6474) manufacturer | order Vandetanib (ZD6474) | Vandetanib (ZD6474) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID